Biotech's tax agenda

Biotech's tax agenda

WASHINGTON - The Biotechnology Industry Organization wants a capital gains incentive as well as a second-tier incentive for emerging companies, changes in IRS net operating loss change of ownership rules, a permanent or extended Research and Experimentation Credit, and a permanent or extended Orphan Drug credit.

Robert Beckman, president and CEO of Intergen Co. LP and chairman of BIO's Emerging

Read the full 628 word article

How to gain access

Continue reading with a
two-week free trial.